Ibrutinib and venetoclax target distinct subpopulations of CLL cells: implication for residual disease eradication.
Ibrutinib and venetoclax target distinct subpopulations of CLL cells: implication for residual disease eradication. Blood Cancer J. 2021 02 18; 11(2):39.